武漢佰樂(lè)博代理：Research Grade Lucatumumab  

貨號(hào)：DHD68905

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75458.html

產(chǎn)品購(gòu)買聯(lián)系方式：027-65279366

產(chǎn)品介紹：Lucatumumab (HCD122)是一種全人抗CD40拮抗劑單克隆抗體，可阻斷CD40/ CD40L介導(dǎo)的信號(hào)通路。Lucatumumab可有效介導(dǎo)抗體依賴性細(xì)胞介導(dǎo)的細(xì)胞毒性(ADCC)和腫瘤細(xì)胞清除，可用于頑固性淋巴瘤、慢性淋巴細(xì)胞白血病(CLL)和多發(fā)性骨髓瘤研究。

通用名：Lucatumumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：CHIR-12, 12, HCD122

靶點(diǎn);物種：Human CD40/TNFRSF5

種類：Homo sapiens

受體鑒定：IgG1-kappa

CAS: 903512-50-5

存儲(chǔ)條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻(xiàn)：

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. PMID: 22475052

Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. PMID: 24219359

Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations. PMID: 26758550

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. PMID: 22861192

Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling. PMID: 31404613

Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. PMID: 24555495

Emerging immune targets for the treatment of multiple myeloma. PMID: 29421983

Emerging antibodies for the treatment of multiple myeloma. PMID: 27195659

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). PMID: 29572070

Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. PMID: 25249370

Interfering with CD40 ligation: a sensitive matter in chronic lymphocytic leukemia. PMID: 22563816